Abstract:Coronary heart disease (CHD) is one of the leading causes of morbidity and mortality worldwide, and more efforts should be made to reduce the risk of cardiovascular events. This study aimed to investigate the impact of clinical pharmacist intervention on the prognosis of acute coronary syndrome (ACS) in Chinese patients with CHD. Two hundred and forty patients who had ACS were recruited. Participants were randomly assigned to the intervention group (n = 120) or the control group (n = 120). The intervention group received a medication assessment and education by the clinical pharmacist at discharge and telephone follow-ups at 1 week and 1 and 3 months after discharge. The control group received usual care. The primary outcomes of this study were the proportion of patients who had major adverse cardiovascular events (MACEs), including mortality, nonfatal myocardial infarction (MI), stroke, and unplanned cardiac-related rehospitalizations within 6 and 12 months after hospital discharge. Secondary outcome was self-reported medication adherence to evidence-based medications for CHD (antiplatelets, statins, β-blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). Of 240 enrolled patients, 238 (98.3%) completed 6-month follow-up, and 235 (97.9%) completed 12-month follow-up. There were no significant differences between intervention and control groups in the percentages of patients who incurred MACEs within the 6-month follow-up (3.3% vs 7.6%, respectively, P = 0.145) or 12-month follow-up (10.9% vs 12.1%, respectively, P = 0.783). Significant improvements were found in the prescribing rates of β-blockers and all four classes of medications at discharge in the intervention group compared with the control group (P = 0.001 and P = 0.009, respectively). There was no significant difference between the intervention and control groups in the use of all four classes of medications at the 6-month follow-up (48.3% vs 45.8%, respectively, P = 0.691) and 12-month follow-up (47.9% vs 46.6%, respectively, P = 0.836). The use of β-blockers was nonsignificantly higher in the intervention group than in the control group at the 6-month follow-up (74.2% vs. 64.4%, P = 0.103) and 12-month follow-up (74.8% vs 63.8%, P = 0.068). Clinical pharmacist intervention had no significant effects on reduction in cardiovascular events among patients with CHD. Further studies with larger sample sizes and longer time frames for both intervention and follow-up are needed to validate the role of the clinical pharmacist in the morbidity and mortality of CHD. Clinical Trial Registration: chictr.org.cn, identifier ChiCTR-IOR-16007716.

Effect of Clinical Pharmacist Intervention on Patients with Acute Cerebral Infarction

Effectiveness of Pharmaceutical Care in an Intensive Care Unit from China A Pre- and Post-Intervention Study

Impacts of Clinical Pharmacist Intervention on the Secondary Prevention of Coronary Heart Disease: A Randomized Controlled Clinical Study.

Clinical Pharmacist Interventions on a Chinese Neurology Ward: a 2-Year Service Evaluation

Effect of clinical pharmacist intervention on compliance of patients with cerebral infarction

Pharmaceutical care on a patient with atrial fibrillation combined with cerebral infarction

Effectiveness of Continuous Improvement by a Clinical Pharmacist-Led Guidance Team on the Prophylactic Antibiotics Usage Rationality in Intervention Procedure at a Chinese Tertiary Teaching Hospital

Effectiveness of Pharmacist Dosing Adjustment for Critically Ill Patients Receiving Continuous Renal Replacement Therapy: a Comparative Study.

Implementation of Pharmacists' Interventions and Assessment of Medication Errors in an Intensive Care Unit of A Chinese Tertiary Hospital

Effect of clinical pharmacists participating in nutritional therapy for patients with acute cerebral infarction complicated with dysphagia

Analysis and Evaluation of the Drug Use on Inpatients with Cerebral Infarction Based on Guideline and Clinical Pathway

Analysis on medication and clinical pathway medication recommendation in inpatients with cerebral infarction

Clinical Pharmacist' Experience of Pharmaceutical Care for One Case of Transient Ischemic Attack

Effect of critical care pharmacist on antibiotic medication optimizations, reduce drug costs but not increase mortality: A retrospective cohort study in the real world research

Benefits of Pharmacist Intervention in the Critical Care Geriatric Patients with Infectious Diseases: A Propensity Score Matching Retrospective Cohort Study

Effect of family-centered nursing based on timing it right framework in patients with acute cerebral infarction

Effects of Glucose Fluctuation Targeted Intervention on the Prognosis of Patients with Type 2 Diabetes Following the First Episode of Cerebral Infarction

Effects of Butylphthalide Injection on Serum IL-6, IL-1β, TNF-α and Prognosis in Patients with Acute Cerebral Infarction

Impact of Pharmacist Antimicrobial Dosing Adjustments in Septic Patients on Continuous Renal Replacement Therapy in an Intensive Care Unit

Effect of antihypertensive drugs in acute phase of cerebral infarction on cognitive impairment after stroke

Effect of Clopidogrel combined with aspirin in the treatment of acute progressive cerebral infarction: A retrospective single-center analysis